Compromised antigen presentation ranks among the top mechanisms that render cancers non-immunogenic (non-responsive to immune ...

Cancer Res (2025) 85 (8_Supplement_1): 4294.

GEN-1013 was studied in an aggressive CT26 murine cancer model using both IT and IV administration.Significant tumor reduction was observed in both administration routes. Both IT and IV were ...

Traditional xenograft tumor models developed in immunodeficient mice are employed to evaluate ADCs' anti-tumor efficacy. However, these models lack competent immune systems and human antigen ...

Discover comprehensive insights into approved therapeutics and research developments targeting Prostate-Specific Membrane Antigen (PSMA). This product provides detailed competitor analysis, R&D stages ...

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.

CDR-Life today announced the presentation of data for its novel T cell engager (TCE) programs at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The presentations ...

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the publication of 3 abstracts for poster presentations at the ...

First preclinical data of novel targeted Radio-DARPin against mesothelin (MSLN), in co-development with Orano Med "Our presentations at AACR highlight the breadth of Molecular Partners' DARPin ...